A multiple ascending subcutaneous (SC) dose study of MEDI-563, a humanized anti-IL-5Rα monoclonal antibody, in adult asthmatics Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD7594 after single and multiple ascending inhaled doses in healthy Japanese males Source: International Congress 2017 – COPD management Year: 2017
Dose escalation study in healthy male subjects to investigate safety, tolerability and systemic exposure of orally inhaled single-doses of AP301 Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012
Safety, tolerability and pharmacokinetics (PK) of AZD8154 (a selective PI3K?d inhibitor) after single ascending inhaled doses in healthy volunteers Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019
Multiple ascending inhaled doses of AZD8871 in healthy males Source: International Congress 2018 – Pharmacological management of COPD Year: 2018
A phase 1 multiple dose safety and pharmacokinetics study of AIR645, an inhaled IL-4rα 2-MOE GAPMER oligonucleotide Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
Airway administration of therapeutic antibody (tAb) confers higher protection than parenteral administration in a murine model of acute lung infection Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018
A phase I single escalating intravenous (IV) dose of MEDI 563, an anti-IL5Rα antibody, in atopic asthma Source: Annual Congress 2008 - New treatments for asthma Year: 2008
Safety and pharmacokinetics study of a single ascending dose of C16TR for inhalation (INS1009) Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016
Inhaled LPS challenge in healthy subjects: a dose escalation study Source: International Congress 2018 – Studies on the mechanisms underlying airway disease Year: 2018
Immunological mechanisms of intravenous roncoleucin (IL-2) clinical effects in asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 512s Year: 2002
The acute protective effect of a single dose of fluticasone propionate (FP) on the allergen-induced early asthmatic response in man Source: Eur Respir J 2002; 20: Suppl. 38, 308s Year: 2002
Pharmacokinetic (PK) and pharmacodynamic (PD) data for inhaled and intranasal corticosteroids (CS) reassessed using a physiological PK/PD model Source: Eur Respir J 2001; 18: Suppl. 33, 147s Year: 2001
Safety profile and clinical activity of multiple subcutaneous (SC) doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in subjects with asthma Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease Year: 2010
Comparison of response to lipopolysaccharide administered by intravenous, orotracheal and inhaled routes in rats Source: Eur Respir J 2007; 30: Suppl. 51, 135s Year: 2007
A multicompartmemt lung model predicts pulmonary pharmacokinetics of inhaled liposomal treprostinil (L606) in healthy volunteer Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19 Source: Eur Respir J, 58 (4) 2100673; 10.1183/13993003.00673-2021 Year: 2021
Both intranasal and intraperitoneal administration of human tubal mesenchymal stem cells (htMSC) ameliorates experimental COPD model Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014
Expression of inflammatory cytokines following stepwise dose reduction of corticosteroids of long-term oral corticosteroids users with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 62s Year: 2004
Late Breaking Abstract - Dose responses for topical efficacy and systemic activity, dose equivalence and relative therapeutic index for fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD) in asthmatic subjects. Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019